New atlas details immune cell changes as disease progresses
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
News
FDA approves Imkeldi, imatinib as oral liquid, for certain leukemias
The U.S. Food and Drug Administration (FDA) has approved an oral liquid formulation of imatinib, now called Imkeldi, to treat specific forms of…
Somatostatin may be safe option for certain tumors during pregnancy
For about one-third of women with a neuroendocrine tumor — or an abnormal mass of tissue that forms from hormone-releasing cells, such as those in…
Vitamin D seen to prevent ovarian cancer’s onset in disease models
Vitamin D may help to prevent the development of ovarian cancers, according to new studies in mice and cell disease models. “These data strongly…
FDA to review combinations of Blenrep for multiple myeloma
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…
FDA approves revumenib for select acute leukemias with KMT2A defect
The U.S. Food and Drug Administration (FDA) has approved revumenib, now called Revuforj, as an oral therapy for children and adults, ages 1 year and…
Treatment before surgery slows PDAC disease progression: Study
Neoadjuvant therapy, or treatment to shrink tumors before the surgery to remove them, delayed disease progression, reduced recurrence, and extended survival in people with pancreatic…
Scientists discover tissue differences in brain cancer in children
U.S. scientists have discovered that pediatric low-grade gliomas — a type of brain cancer that can occur in children — are generally softer than normal…
Elahere approved in EU as treatment for ovarian cancer
AbbVie’s Elahere (mirvetuximab soravtansine) has been approved in the European Union to treat adults with advanced ovarian, fallopian tube, or primary peritoneal cancer whose…
November 19, 2024
by Marisa Wexler, MS
Survival better with Blenrep combo than Darzalex for R/R myeloma
A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple myeloma than a combo treatment…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML